FDA Proposes Crackdown on Bulk Compounding of Blockbuster Weight Loss Drugs

The U.S. Food and Drug Administration announced a proposal on Thursday to exclude the active ingredients of several blockbuster obesity and diabetes medications from the list of substances that outsourcing facilities can use for bulk compounding. If finalized, this move would significantly curtail the production of cheaper, custom-made alternatives to branded medications. The proposal specifically targets 503B outsourcing facilities, which manufacture compounded drugs in bulk. According to FDA Commissioner Marty Makary, there is 'no clinical need' for these facilities to compound these specific drugs when FDA-approved versions are readily available. The restriction would only be waived if the medications are officially added to the FDA's drug shortage list. Key substances targeted in the proposal include semaglutide, the active ingredient in Novo Nordisk's Wegovy and Ozempic, and tirzepatide, found in Eli Lilly's Zepbound and Mounjaro. The proposal also encompasses Novo Nordisk's older molecule, liraglutide. This regulatory shift comes as both pharmaceutical giants have invested billions of dollars to expand their manufacturing capacity and alleviate previous supply constraints. While 503B facilities would be restricted, the proposal does not impact 503A pharmacies, which prepare medications for individual patients based on specific prescriptions and are primarily regulated at the state level. The FDA will consider public comments on the proposal through late June before reaching a final decision. For Novo Nordisk and Eli Lilly, the move represents a major victory in protecting their intellectual property and market dominance. Both companies have recently attempted to make their branded versions more affordable to lure patients away from the lower-cost compounded market.